

Expression pattern of circulating long non-coding RNA *GAS5* as a novel biomarker in non-small cell lung cancer patients

Natasa Vesovic¹, Natasa Tomic^{2*}, Teodora Karan Djurasevic², Zoran Andric³, Darko Zdravkovic³, Sonja Pavlovic², Dragana Jovanovic⁴

¹Clinic for Chest Surgery, Medical Military Academy, Belgrade, Serbia

²Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia

³Clinics for Oncology, University Hospital Medical Centre Bezanijska Kosa, Belgrade, Serbia

⁴University Hospital of Pulmonology, Clinical Centre of Serbia, Belgrade, Serbia

Submitted: 8 April 2020; **Accepted:** 13 June 2020

Online publication: 9 September 2020

Arch Med Sci 2026; 22 (1): 469–475

DOI: <https://doi.org/10.5114/aoms.2020.98815>

Copyright © 2020 Termedia & Banach

***Corresponding author:**

Natasa Tomic, PhD
Institute of Molecular
Genetics
and Genetic Engineering
University of Belgrade
Belgrade, Serbia
E-mail: natasa.tomic@imgge.bg.ac.rs

Abstract

Introduction: The finding that long noncoding RNAs (lncRNAs) originating from tumor cells could be found in general circulation has prompted the idea to use lncRNAs as noninvasive diagnostic biomarkers of particular diseases. In this study we explored the expression pattern of circulating *GAS5* (growth arrest-specific transcript 5) lncRNA in non-small cell lung cancer (NSCLC) patients and its association with clinicopathological characteristics.

Material and methods: Expression pattern of circulating *GAS5* was analyzed in 58 plasma samples of NSCLC patients, and 15 healthy controls. Quantitative assessment was performed using the real-time PCR method and TaqMan chemistry.

Results: Circulating *GAS5* expression level in NSCLC patients was not significantly decreased compared to control samples ($p = 0.081$). Statistically significant difference in *GAS5* expression was found in relation to TNM stage of the tumor ($p < 0.001$), decreasing with progression of the tumor stage. Lower *GAS5* expression was detected in patients with larger tumors ($p = 0.006$), and in patients with lymph node metastasis ($p = 0.001$). Receiver operating characteristic curve analysis was used to evaluate the diagnostic potential of circulating *GAS5* expression, showing the highest predictive power in distinguishing between stage III/IV patients and control samples (AUC = 0.8; sensitivity 53%, specificity 93%), and also for separating patients between TNM stage I/II and stage III/IV (AUC = 0.82; sensitivity 73%, specificity 79%).

Conclusions: Our study suggests that decreased expression of circulating *GAS5* is closely related to the tumor size and TNM stage. Therefore the measurement of *GAS5* expression level in plasma could be a promising noninvasive diagnostic molecular biomarker in NSCLC patients.

Key words: non-small cell lung cancer, plasma RNA, long non-coding RNA, *GAS5*.

Introduction

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, which can be found in about 85% of cases [1]. There are three

histological subtypes of NSCLC: adenocarcinoma (AC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC) [2]. Regardless of the great improvement in the treatment of NSCLC, including targeted chemotherapy and radiotherapy, 5-year survival of these patients is only 15% [3]. Treatment approach depends primarily on the stage of the disease, and, as one of the main features of NSCLC is its asymptomatic nature, this type of cancer is usually diagnosed in an advanced stage, when conventional therapy is not efficient. Therefore, the mortality among NSCLC patients remains high [4].

In the current research of NSCLC there is a constant need for the discovery of novel biomarkers with high specificity and sensitivity, which could be used in early diagnosis. Also, new biomarkers could serve as targets for the application of new therapy. The discovery that nucleic acids originating from cancer cells can be found in the peripheral circulation of cancer patients has had a major impact towards development of noninvasive techniques for the detection of new molecular biomarkers that can be used in diagnosis of different types of cancers, including NSCLC [5].

In recent years, much attention has been focused on long noncoding RNAs (lncRNAs) and their role in cancer pathology [6–9]. lncRNAs are defined as transcribed RNA molecules with length greater than 200 nucleotides. They are not translated into protein, but are involved in gene regulation and genome activity. Also, they represent an important element of epigenetic regulation of the nuclear and mitochondrial genome, and the disturbances in lncRNA functioning underlie a number of diseases, not just cancer [10, 11]. Consequently, they regulate main cell processes such as differentiation, proliferation and the cell cycle [12, 13]. lncRNA originating from the primary tumor cells can be detected in the plasma of cancer patients. Expression pattern of numerous lncRNAs has been studied in NSCLC patients [14, 15]. Among them *GAS5* (growth arrest-specific transcript 5) could be the most promising new molecular biomarker for distinguishing NSCLC patients from noncancerous subjects [16, 17].

The *GAS5* gene, located at the 1q25 locus, is approximately 650 base pairs in length and it is organized in 12 exons and 11 introns. Introns encode 10 box C/D snoRNAs (small nucleolar RNAs) that are involved in the methylation process, and therefore in epigenetic regulation. Exons encode few splice variants of *GAS5* mRNA, but due to the presence of a stop codon, none of them produce protein, and transcripts are degraded through the nonsense mediated decay (NMD) pathway [18]. The expression level of

GAS5 is increased during growth arrest by serum deprivation [19]. On the other hand, *GAS5* is down-regulated in many types of cancer including NSCLC, indicating tumor suppressor function of this lncRNA [20]. It has been proven that increased expression of *GAS5* induces apoptosis *in vitro*, and reduces tumor growth *in vivo* [21]. Also, it was shown that up-regulation of *GAS5* in NSCLC suppresses cell proliferation, growth and invasion of tumor cells [22, 23].

In the present study we examined the expression pattern of circulating *GAS5* in the plasma samples of NSCLC patients and in healthy individuals, and investigated the association between *GAS5* expression level and patients' clinicopathological features. Also, we evaluated whether *GAS5* expression level could serve as novel, noninvasive molecular biomarker in NSCLC diagnosis.

Material and methods

Patients

Samples of 58 patients diagnosed with NSCLC (median 65 years, range 45–81) and 15 healthy controls were collected from UHMC Bezanijska Kosa, Belgrade, from May 2018 to March 2019. Samples were collected from the patients before any kind of treatment. The study was approved by the Ethics Committee of the UHMC Bezanijska Kosa, Belgrade, and all of the participants signed an informed consent form according to the principles of the Declaration of Helsinki.

All patients underwent diagnostic procedures that included bronchoscopy, CT scan of the chest and abdomen, skeletal scintigraphy and brain MRI. Patients were assigned to the appropriate stage according to the post-surgical pathohistological findings (TNM classification). All of the clinical and pathological data of patients are displayed in Table I.

Plasma preparation and RNA extraction

For each patient and healthy controls blood samples were collected in 9 ml EDTA anti-coagulation tubes and were kept at 4°C and then transported to the Institute of Molecular Genetics and Genetic Engineering for further processing. Plasma was separated within 4 h after collection using a two-step centrifugation protocol. First, blood samples were centrifuged for 10 min at 1900 g, at 4°C, and then a second centrifugation step was performed to eliminate any cell debris (10 min at 16 000 g, at 4°C). Supernatant was collected in aliquots of 500 µl and stored at –80°C.

Total RNA extraction was performed using the miRNeasy Serum/Plasma Kit (Qiagen, Germany) and vacuum manifold QIAvac24 Plus (Qiagen, Germany), with slight modifications of the manufac-

turer's protocol. The volume of starting material was raised to 500 μ l as it was suggested by the NIH Extracellular RNA Communication Consortium [24]. The volume ratio between plasma, Qiazol LR and chloroform was kept constant at 1 : 5 : 1, and additional washing steps were performed when using RPE buffer and 80% ethanol. Finally, double elution was performed using 30 μ l of RNase-free water. The final RNA yield ranged from 200–750 ng, per 500 μ l of plasma.

Quantitative reverse transcription polymerase chain reaction (qRT-PCR)

Total RNA (400 ng) was reverse transcribed into cDNA using RevertAid Reverse Transcriptase (Thermo Scientific). Real time-PCR was performed with the 7900 HT Fast Real-Time PCR System (Applied Biosystems). We performed PCR using 1 μ l of cDNA (20 ng RNA equivalent) with TaqMan Universal Master Mix II (Applied Biosystems), and pre-designed (ready-to-go) TaqMan Gene Expression Assay for *GAS5* (Hs03464472_m1) and for *GAPDH* (Hs99999905_m1) as an endogenous control (Thermo Fisher Scientific). All samples were run in duplicate. The PCR reaction was performed at 95°C for 10 min, followed by 50 cycles of 95°C for 15 s, and 60°C for 1 min. Relative quantification analysis was performed using the comparative $ddCt$ method, using healthy controls as a calibrator, meaning $ddCt = dCt_{sample} - dCt_{healthy\ control\ (median)}$.

Statistical analysis

The data were descriptively reported as medians with range, means \pm SD, or as absolute numbers with percentages. Differences in continuous variables were analyzed using the Mann-Whitney *U* test for distribution between two groups. Receiver operating curve (ROC) curve analysis was done to evaluate predictive power of *GAS5* expression level in diagnosis and staging of NSCLC patients.

The statistical analyses were performed using the SPSS computer software 21.0 (IBM). For all analyses, the *p*-values were 2-tailed, and *p* < 0.05 was considered statistically significant.

Results

GAS5 expression and clinicopathological features

The expression level of *GAS5* was evaluated in a cohort of 58 NSCLC patients and in 15 healthy individuals. The median expression level of *GAS5* among patients was 0.65 (range: 0.00–3.76), which was not significantly lower compared to the expression level found among healthy individuals (median 1.00 \pm 1.30, range: 0.15–4.31,

p = 0.081). Also, *GAS5* expression level in the patients' plasma samples was not significantly correlated with age, gender, smoking status or histology type (Table I). On the other hand, comparing *GAS5* expression between the patients with different tumor sizes (smaller and larger than 3 cm) we detected a statistically significantly lower value in patients with larger tumors (*p* = 0.006) (Figure 1 A).

We also detected a statistically significant difference in *GAS5* expression in relation to TNM stage of the tumor (Table I). When analyzing individual associations between TNM stages, we detected the largest statistical difference between stage III patients and all other stages (Figure 1 B). When we analyzed *GAS5* expression in NSCLC patients at different T stages, we observed that *GAS5* expression decreased slowly as the T-stage increased. Significant differences were detected between T1 and T3/T4 stages (*p* = 0.016 and *p* = 0.003, respectively) (Figure 1 C).

Significant differences in *GAS5* expression were detected regarding the presence of lymph node metastasis (*p* = 0.001). Patients positive for these metastasis had much lower expression of *GAS5* compared to patients without lymph node involvement (Figure 1 D).

Diagnostic potential of *GAS5* expression in NSCLC

We used ROC curve analysis to calculate the predictive power of *GAS5* expression to discriminate between NSCLC patients and healthy individuals. In our cohort of patients the value of AUC was 0.65 (95% CI: 0.5–0.794) (*p* = 0.081), and the sensitivity and specificity were 24% and 100%, for the cut-off value of 0.135 (Figure 2 A).

Compared to healthy control samples, only *GAS5* expression detected in stage III patients gave a significant predictive value in ROC curve analysis with AUC = 0.93 (95% CI: 0.842–1.024) (*p* < 0.001), sensitivity 87% and specificity 93% (cut-off value 0.18) (Figure 2 B). Also, when we combined stage III and stage IV patients and compared them to control samples, circulating *GAS5* expression showed significant predictive value with AUC = 0.80 (95% CI: 0.668–0.928) (*p* = 0.001), sensitivity 53% and specificity 93% (cut-off value 0.18) (Figure 2 C).

Next, we evaluated whether based on *GAS5* expression we could distinguish NSCLC patients at different TNM stages. Patients with stage I and stage II tumors were compared to patients with stage III or stage IV tumors and ROC curve analysis showed strong predictive power with AUC of 0.82 (95% CI: 0.710–0.923) (*p* < 0.001), 73% sensitivity and specificity of 79% (cut-off value 0.64) (Figure 2 D).

Table I. Association of *GAS5* expression with clinicopathological characteristics of patients with NSCLC

| Variable | No of patients (N = 58) | <i>GAS5</i> expression | P-value |
|------------------------|-------------------------|------------------------|---|
| Gender (%): | | | 0.347 |
| Male | 41 (71) | 0.60 (0.02–3.76) | |
| Female | 17 (29) | 0.97 (0.00–3.19) | |
| Age (years) (%): | | | 0.668 |
| ≤ 65 | 27 (47) | 0.65 (0.03–3.19) | |
| > 65 | 31 (53) | 0.65 (0.00–3.76) | |
| Smoking status (%): | | | 0.872 |
| Yes | 53 (91) | 0.65 (0.02–3.76) | |
| No | 5 (9) | 0.80 (0.00–2.60) | |
| Tumor size (%): | | | 0.006 |
| ≤ 3 cm | 13 (22) | 1.58 (0.38–3.76) | |
| > 3 cm | 45 (78) | 0.53 (0.00–3.19) | |
| Histology type (%): | | | 0.242 |
| Adenocarcinoma | 28 (48) | 0.66 (0.00–3.76) | |
| Squamous carcinoma | 26 (45) | 0.64 (0.05–3.19) | |
| Non-microcellular | 4 (7) | 0.13 (0.08–0.68) | |
| TNM stage (%): | | | < 0.001 |
| I | 16 (28) | 1.22 (0.08–3.76) | < 0.001 (I vs. III) |
| IA | 10 | 2.36 (0.38–3.76) | < 0.001 (IA vs. III), 0.036 (IA vs. IV) |
| IB | 6 | 1.00 (0.08–3.10) | |
| II | 12 (21) | 1.12 (0.41–3.19) | < 0.001 (II vs. III) |
| III | 15 (26) | 0.09 (0.00–1.16) | |
| IV | 15 (26) | 0.63 (0.03–2.41) | 0.002 (IV vs. III) |
| T stage (%): | | | 0.016 |
| T1 | 12 (21) | 1.91 (0.38–3.76) | |
| T2 | 15 (26) | 0.68 (0.03–3.10) | |
| T3 | 17 (29) | 0.57 (0.00–3.19) | 0.016 (T3 vs. T1) |
| T4 | 14 (24) | 0.16 (0.03–2.41) | 0.003 (T4 vs. T1) |
| Lymph node metastasis: | | | 0.001 |
| Negative | 27 (47) | 1.20 (0.05–3.76) | |
| Positive | 31 (53) | 0.48 (0.00–2.41) | |

Discussion

In recent years, a lot of attention has been given to the study of the role of long noncoding RNAs in different cancers, including non-small lung cancer (NSCLC). The fact that lncRNAs are relatively stable in plasma samples has prompted the idea to use them as noninvasive diagnostic molecular

markers of the disease. In this study we investigated the expression pattern of *GAS5*, lncRNA with a known functional role in NSCLC pathogenesis.

We found that *GAS5* expression level was not significantly downregulated in patients compared to healthy individuals. A similar finding was reported by Tan *et al.* although they detected a difference between stage I patients and healthy




Figure 1. Box-plot presentation of *GAS5* expression level in relation to: **A** – tumor size, **B** – TNM stage of the tumor, **C** – T stage of the tumor, **D** – presence of lymph node metastasis

controls, but this difference was marginally significant ($p = 0.049$) [17]. In our cohort of patients we were unable to replicate this finding even when we separated stage I patients into IA and IB stage (Figure 1 B). Still, we detected a decrease in *GAS5* expression in stage IB compared to stage IA (2.36 vs. 1.00, Figure 1 B) and that value in stage IB is more similar to the one detected in stage II (1.12). Moreover, based on *GAS5* expression level we could clearly discriminate patients with stage III tumor from the control group ($p < 0.001$), and all other TNM stages (Table I). Similar results are reported by two other studies dedicated entirely to analyzing *GAS5* expression in plasma samples of NSCLC patients, where a significant decrease in *GAS5* expression was detected in later TNM stages [16, 25]. We assume that uneven values of *GAS5* expression, i.e. non-linear decrease through TNM stages detected in previously mentioned studies (as well as in this one), primarily reflect different approaches in the calculation of relative *GAS5* expression, and also the overall small number of patients. Also, when determining *GAS5* expression in NSCLC patients the origin of the sample should

be taken into account. Namely, Tan *et al.* analyzed paired tissue/plasma samples and found that the decrease in *GAS5* expression observed with progression of TNM tumor stages is detected within tissue samples, but not in plasma samples from the same NSCLC patients [17].

Moreover, we found that circulating *GAS5* is a great predictor of tumor size, since patients with a tumor larger than 3 cm had significantly diminished expression compared to patients with a tumor ≤ 3 cm. This result, which was also reported by others, can be interpreted through known tumor-suppressor function of *GAS5* [21]. Consistent with this tumor-suppressor function is our finding that *GAS5* expression level differed between tumor T-stages, i.e. *GAS5* expression level decreased with increasing T stage of the tumor.

GAS5 also plays a role in tumorigenesis by contributing to the formation of metastases [22]. In our cohort, NSCLC patients with regional lymph node metastasis had significantly diminished *GAS5* expression in comparison to patients without such metastasis. Recently in *in vitro* experiments it was found that suppression




Figure 2. Receiver operating characteristic (ROC) curve for *GAS5* expression levels discriminating between: **A** – whole cohort of NSCLC patients and healthy controls, **B** – TNM stage III NSCLC patients and healthy controls, **C** – TNM stage III and IV NSCLC patients and healthy controls, **D** – TNM stage I/II and stage III/IV NSCLC patients

of *GAS5* enables the increase of cell migration and invasion, and in that way contributes to the progression of NSCLC. An even more significant finding of these experiments was that *GAS5* expression was observed to be controlled by PTEN (phosphatase and tensin homolog), a tumor-suppressor protein. More precisely, the existence of this *GAS5*/miR-205/PTEN axis was detected [23]. *GAS5* suppresses cell proliferation, migration and invasion through inhibition of miR-205. miR-205 inhibits PTEN expression by interfering with PTEN translational regulation. Inhibition of miR-205 through *GAS5* directly leads to overexpression of PTEN and evident tumor suppressor effect. Thus, regulation of the PTEN signaling pathway may serve for application of new targeted NSCLC therapy [23].

Analyzing the potential of *GAS5* expression level as a diagnostic tool, we did not observe its importance in distinguishing between early stage tumor patients (stage I/II) and healthy controls. A clear distinction was observed only in stage III patients. In other studies, similar results were reported, but they also reported the diagnostic potential of combined *GAS5* expression with tumor markers such as CEA, SCCA and CYFRA21-1, and also with other lncRNAs such as *SOX2OT* and *ANRIL* [16, 25]. It seems that more accurate differential diagnosis can be achieved by combining *GAS5* expression level with other markers.

Our study showed that expression of plasma *GAS5* was down-regulated in NSCLC patients. Degree of the decrease in *GAS5* expression was associated with progression of TNM tumor stage,

and also with the tumor size and the presence of lymph node metastasis. In addition, *GAS5* expression showed significant predictive value for distinguishing between stage III/IV NSCLC patients and control subjects, as well as between patients in different TNM stages. Based on this, we can conclude that *GAS5* expression level shows potential to be used as a noninvasive diagnostic molecular marker in NSCLC patients.

Still, this study has a few limitations, involving, primarily, small sample size for both NSCLC and healthy controls. Further investigations on larger numbers of patients would determine the true value of plasma *GAS5* expression level as an early prognostic biomarker for NSCLC. We also propose the standardization of methodology used for plasma RNA isolation and real-time-PCR quantification of *GAS5*, in order to set a “universal” cut-off value that would discriminate between healthy individuals and early stage NSCLC patients. Without such standardization, the introduction of this noninvasive method for the detection of *GAS5* as a new biomarker is still far away from everyday clinical practice.

Funding

This work was funded by the Ministry of Education, Science and Technological Development, Republic of Serbia (grant number III 41004).

Conflict of interest

The authors declare no conflict of interest.

References

- Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. *J Natl Compr Cancer Netw* 2010; 8: 740-801.
- Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. *Lancet* 2011; 378: 1727-40.
- DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics. *CA Cancer J Clin* 2014; 64: 252-71.
- Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. *Lancet* 2013; 382: 720-31.
- Rapisuwon S, Vietsch EE, Wellstein A. Circulating biomarkers to monitor cancer progression and treatment. *Comput Struct Biotechnol J* 2016; 4: 211-22.
- Jiang L, Hong L, Yang W, Zhao Y, Tan A, Li Y. Co-expression network analysis of the lncRNAs and mRNAs associated with cervical cancer progression. *Arch Med Sci* 2019; 15: 754-64.
- Gasic V, Stankovic B, Zukic B, et al. Expression pattern of long non-coding RNA growth arrest-specific 5 in the remission induction therapy in childhood acute lymphoblastic leukemia. *J Med Biochem* 2019; 38: 292-8.
- Peng Z, Zhang C, Duan C. Functions and mechanisms of long noncoding RNAs in lung cancer. *Onco Targets Ther* 2016; 9: 4411-24.
- Xu R, Han Y. Long non-coding RNA FOXF1 adjacent non-coding developmental regulatory RNA inhibits growth and chemotherapy resistance in non-small cell lung cancer. *Arch Med Sci* 2019; 15: 1539-46.
- Schmitz SU, Grote P, Herrmann BG. Mechanisms of long noncoding RNA function in development and disease. *Cell Mol Life Sci* 2016; 73: 2491-509.
- Fila M, Pawłowska E, Blasiak J. Mitochondria in migraine pathophysiology – does epigenetics play a role? *Arch Med Sci* 2019; 15: 944-56.
- Liu X, Wang M, Cui Y. LncRNA TP73-AS1 interacted with miR-141-3p to promote the proliferation of non-small cell lung cancer. *Arch Med Sci* 2019; 15: 1547-54.
- Liu H, Zhang Q, Lou Q, et al. Differential analysis of lncRNA, miRNA and mRNA expression profiles and the prognostic value of lncRNA in esophageal cancer. *Pathol Oncol Res* 2020; 26: 1029-39.
- Hu X, Bao J, Wang Z, et al. The plasma lncRNA acting as fingerprint in non-small-cell lung cancer. *Tumour Biol* 2016; 37: 3497-504.
- Lin Y, Leng Q, Zhan M, Jiang F. A plasma long noncoding RNA signature for early detection of lung cancer. *Transl Oncol* 2018; 11: 1225-31.
- Liang W, Lv T, Shi X, et al. Circulating long noncoding RNA GAS5 is a novel biomarker for the diagnosis of non-small cell lung cancer. *Medicine (Baltimore)* 2016; 95: e4608.
- Tan Q, Zuo J, Qiu S, et al. Identification of circulating long non-coding RNA GAS5 as a potential biomarker for non-small cell lung cancer diagnosis, long non-coding RNA, plasma, GAS5, biomarker. *Int J Oncol* 2017; 50: 1729-38.
- Williams GT, Mourtada-Maarabouni M, Farzaneh F. A critical role for non-coding RNA GAS5 in growth arrest and rapamycin inhibition in human T-lymphocytes. *Biochem Soc Trans* 2011; 39: 482-6.
- Fleming JV, Hay SM, Harries DN, Rees WD. Effects of nutrient deprivation and differentiation on the expression of growth-arrest genes (*gas* and *gadd*) in F9 embryonal carcinoma cells. *Biochem J* 1998; 330: 573-9.
- Ma C, Shi X, Zhu Q, et al. The growth arrest-specific transcript 5 (GAS5): a pivotal tumor suppressor long noncoding RNA in human cancers. *Tumour Biol* 2016; 37: 1437-44.
- Shi X, Sun M, Liu H, Yao Y, Kong R, Chen F. A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small-cell lung cancer. *Mol Carcinog* 2015; 54: E1-12.
- Wu Y, Lyu H, Liu H, Shi X, Song Y, Liu B. Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer. *Sci Rep* 2016; 6: 31093.
- Dong L, Li G, Li Y, Zhu Z. Upregulation of long noncoding RNA GAS5 inhibits lung cancer cell proliferation and metastasis via miR-205/PTEN axis. *Med Sci Monit* 2019; 25: 2311-9.
- Laurent LC, Abdel-Mageed AB, Adelson PD, et al. Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. *J Extracell Vesicles* 2015; 4: 26533.
- Kamel LM, Atef DM, Mackawy AMH, Shalaby SM, Abdelraheim N. Circulating long non-coding RNA GAS5 and SOX2OT as potential biomarkers for diagnosis and prognosis of non-small cell lung cancer. *Biotechnol Appl Biochem* 2019; 66: 634-42.